[go: up one dir, main page]

DE69837809D1 - Apolipoprotein a-i agonisten sowie deren verwendung zur behandlung dislipidemischer erkrankungen - Google Patents

Apolipoprotein a-i agonisten sowie deren verwendung zur behandlung dislipidemischer erkrankungen

Info

Publication number
DE69837809D1
DE69837809D1 DE69837809T DE69837809T DE69837809D1 DE 69837809 D1 DE69837809 D1 DE 69837809D1 DE 69837809 T DE69837809 T DE 69837809T DE 69837809 T DE69837809 T DE 69837809T DE 69837809 D1 DE69837809 D1 DE 69837809D1
Authority
DE
Germany
Prior art keywords
agonists
dislipidemic
apolipoprotein
illnesses
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69837809T
Other languages
English (en)
Other versions
DE69837809T2 (de
Inventor
Jean-Louis Dasseux
Renate Sekul
Klaus Buttner
Isabelle Cornut
Gunther Metz
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
DASSEUX JEAN LOUIS
Original Assignee
DASSEUX JEAN LOUIS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by DASSEUX JEAN LOUIS filed Critical DASSEUX JEAN LOUIS
Publication of DE69837809D1 publication Critical patent/DE69837809D1/de
Application granted granted Critical
Publication of DE69837809T2 publication Critical patent/DE69837809T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/001—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof by chemical synthesis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/775—Apolipopeptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biophysics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biochemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Toxicology (AREA)
  • Cardiology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Diabetes (AREA)
  • Vascular Medicine (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Obesity (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
DE69837809T 1997-09-29 1998-09-28 Apolipoprotein a-i agonisten sowie deren verwendung zur behandlung dislipidemischer erkrankungen Expired - Lifetime DE69837809T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US940096 1997-09-29
US08/940,096 US6046166A (en) 1997-09-29 1997-09-29 Apolipoprotein A-I agonists and their use to treat dyslipidemic disorders
PCT/US1998/020326 WO1999016458A1 (en) 1997-09-29 1998-09-28 Apolipoprotein a-i agonists and their use to treat dyslipidemic disorders

Publications (2)

Publication Number Publication Date
DE69837809D1 true DE69837809D1 (de) 2007-07-05
DE69837809T2 DE69837809T2 (de) 2008-01-31

Family

ID=25474219

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69837809T Expired - Lifetime DE69837809T2 (de) 1997-09-29 1998-09-28 Apolipoprotein a-i agonisten sowie deren verwendung zur behandlung dislipidemischer erkrankungen

Country Status (18)

Country Link
US (5) US6046166A (de)
EP (1) EP1019074B1 (de)
JP (1) JP2001517710A (de)
KR (1) KR100650953B1 (de)
CN (2) CN1198640C (de)
AT (1) ATE362766T1 (de)
AU (2) AU746686B2 (de)
CA (1) CA2304988C (de)
DE (1) DE69837809T2 (de)
ES (1) ES2287982T3 (de)
HU (1) HUP0103114A3 (de)
IL (1) IL135319A0 (de)
NO (1) NO329204B1 (de)
NZ (1) NZ503718A (de)
PL (1) PL196676B1 (de)
RU (1) RU2214831C2 (de)
UA (1) UA71552C2 (de)
WO (1) WO1999016458A1 (de)

Families Citing this family (107)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6004925A (en) * 1997-09-29 1999-12-21 J. L. Dasseux Apolipoprotein A-I agonists and their use to treat dyslipidemic disorders
US6046166A (en) * 1997-09-29 2000-04-04 Jean-Louis Dasseux Apolipoprotein A-I agonists and their use to treat dyslipidemic disorders
CA2407083A1 (en) * 2000-04-21 2001-11-01 Amgen Inc. Apo-ai/aii peptide derivatives
US7439052B2 (en) * 2000-06-29 2008-10-21 Lipid Sciences Method of making modified immunodeficiency virus particles
US7407662B2 (en) * 2000-06-29 2008-08-05 Lipid Sciences, Inc. Modified viral particles with immunogenic properties and reduced lipid content
US7407663B2 (en) * 2000-06-29 2008-08-05 Lipid Sciences, Inc. Modified immunodeficiency virus particles
US20090017069A1 (en) * 2000-06-29 2009-01-15 Lipid Sciences, Inc. SARS Vaccine Compositions and Methods of Making and Using Them
AUPQ846900A0 (en) * 2000-06-29 2000-07-27 Aruba International Pty Ltd A vaccine
US8568766B2 (en) 2000-08-24 2013-10-29 Gattadahalli M. Anantharamaiah Peptides and peptide mimetics to treat pathologies associated with eye disease
US7166578B2 (en) 2000-08-24 2007-01-23 The Regents Of The University Of California Orally administered peptides synergize statin activity
US7723303B2 (en) * 2000-08-24 2010-05-25 The Regents Of The University Of California Peptides and peptide mimetics to treat pathologies characterized by an inflammatory response
US7144862B2 (en) * 2000-08-24 2006-12-05 The Regents Of The University Of California Orally administered peptides to ameliorate atherosclerosis
US6664230B1 (en) * 2000-08-24 2003-12-16 The Regents Of The University Of California Orally administered peptides to ameliorate atherosclerosis
US7148197B2 (en) * 2000-08-24 2006-12-12 The Regents Of The University Of California Orally administered small peptides synergize statin activity
US7199102B2 (en) 2000-08-24 2007-04-03 The Regents Of The University Of California Orally administered peptides synergize statin activity
US6991727B2 (en) * 2001-06-25 2006-01-31 Lipid Sciences, Inc. Hollow fiber contactor systems for removal of lipids from fluids
US20030104350A1 (en) * 2001-06-25 2003-06-05 Bomberger David C. Systems and methods using a solvent for the removal of lipids from fluids
US7033500B2 (en) * 2001-06-25 2006-04-25 Lipid Sciences, Inc. Systems and methods using multiple solvents for the removal of lipids from fluids
EP1409108A4 (de) * 2001-06-25 2007-11-14 Lipid Sciences Inc Hohlfaserberührungssysteme zur entfernung von lipiden aus fluiden
US20060060520A1 (en) * 2001-06-25 2006-03-23 Bomberger David C Systems and methods using a solvent for the removal of lipids from fluids
IL161109A0 (en) * 2001-09-28 2004-08-31 Esperion Therapeutics Inc Methods and apparatus for extrusion of vesicles at high pressure
US8119590B2 (en) * 2001-09-28 2012-02-21 Cedars-Sinai Medical Center Prevention and treatment of restenosis by local administration of drug
US7470659B2 (en) * 2001-12-07 2008-12-30 The Regents Of The University Of California Methods to increase reverse cholesterol transport in the retinal pigment epithelium (RPE) and Bruch's membrane (BM)
US20030229062A1 (en) * 2001-12-07 2003-12-11 The Regents Of The University Of California Treatments for age-related macular degeneration (AMD)
US6930085B2 (en) 2002-04-05 2005-08-16 The Regents Of The University Of California G-type peptides to ameliorate atherosclerosis
US20040009216A1 (en) * 2002-04-05 2004-01-15 Rodrigueza Wendi V. Compositions and methods for dosing liposomes of certain sizes to treat or prevent disease
NZ537006A (en) * 2002-05-17 2008-01-31 Esperion Therapeutics Inc The use of apolipoprotein A-I Milano, for the manufacture ofa composition for treating preventing or reducing ischemic reperfusion injury in a tissue or organ
JP2006507223A (ja) * 2002-05-17 2006-03-02 エスペリオン セラピューティクス，インコーポレイテッド 脂質代謝異常疾患の治療方法
NL1020962C2 (nl) * 2002-06-28 2003-12-30 Tno Therapie en prognose/monitoring bij sepsis en septische shock.
EP1534243A4 (de) * 2002-08-26 2008-08-13 Lipid Sciences Inc Behandlung von alzheimer mit entlipidierten protein-teilchen
PT2368565E (pt) * 2003-07-03 2015-10-19 Hdl Therapeutics Inc Enriquecimento de lipoproteínas pré-beta de alta densidade
US7393826B2 (en) 2003-07-03 2008-07-01 Lipid Sciences, Inc. Methods and apparatus for creating particle derivatives of HDL with reduced lipid content
US6960803B2 (en) * 2003-10-23 2005-11-01 Silicon Storage Technology, Inc. Landing pad for use as a contact to a conductive spacer
WO2005068020A1 (en) 2004-01-02 2005-07-28 Advanced Cardiovascular Systems, Inc. High-density lipoprotein coated medical devices
US8926958B2 (en) * 2004-04-06 2015-01-06 Cedars-Sinai Medical Center Prevention and treatment of vascular disease with recombinant adeno-associated virus vectors encoding apolipoprotein A-I and apolipoprotein A-I milano
JP2008513479A (ja) * 2004-09-16 2008-05-01 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア アテローム性動脈硬化症および他の病理を改善するためのｇ型ペプチドおよび他の薬剤
ATE469174T1 (de) 2004-10-15 2010-06-15 Us Gov Health & Human Serv Amphipathische helixförmige multidomänenpeptide und verfahren zu deren anwendung
EP1827472A4 (de) 2004-12-06 2012-09-05 Univ California Verfahren zur verbesserung der struktur und funktion von arteriolen
US8206750B2 (en) 2005-03-24 2012-06-26 Cerenis Therapeutics Holding S.A. Charged lipoprotein complexes and their uses
EP2368561B1 (de) * 2005-04-29 2013-12-04 The Regents of The University of California Peptide und Peptidmimetika zur Behandlung von Pathologien, die durch eine Entzündungsreaktion gekennzeichnet sind
US20080293639A1 (en) * 2005-04-29 2008-11-27 The Regents Of The University Of California Peptides and peptide mimetics to treat pathologies characterized by an inflammatory response
US20070254832A1 (en) * 2006-02-17 2007-11-01 Pressler Milton L Methods for the treatment of macular degeneration and related eye conditions
US8163699B2 (en) * 2006-06-01 2012-04-24 Montreal Heart Institute Method for the treatment of valvular disease
US20080227686A1 (en) * 2006-06-16 2008-09-18 Lipid Sciences, Inc. Novel Peptides that Promote Lipid Efflux
EP2041174A2 (de) * 2006-06-16 2009-04-01 Lipid Sciences, Inc. Neue, den lipidausstrom fördernde peptide
US20080206142A1 (en) * 2006-06-16 2008-08-28 Lipid Sciences, Inc. Novel Peptides That Promote Lipid Efflux
US20080138284A1 (en) * 2006-09-26 2008-06-12 Lipid Sciences, Inc. Novel Peptides That Promote Lipid Efflux
FR2913295B1 (fr) * 2007-03-02 2010-09-10 Sagem Comm Procede de telechargement dans un boitier recepteur/ decodeur de television.
WO2008156873A2 (en) * 2007-06-20 2008-12-24 Merck & Co., Inc. Apoa-1 peptide mimetics
DK2190987T3 (da) * 2007-08-21 2013-02-18 Morphosys Ag Fremgangsmåder til dannelse af disulfidbindinger
JP2010537638A (ja) 2007-08-28 2010-12-09 ユーエービー リサーチ ファウンデーション 合成アポリポ蛋白質ｅ模倣ポリペプチドおよび使用方法
CA2704729C (en) 2007-08-28 2020-06-23 Uab Research Foundation Synthetic apolipoprotein e mimicking polypeptides and methods of use
US8044021B2 (en) * 2007-09-20 2011-10-25 Abbott Cardiovascular Systems Inc. Sustained release of apo A-I mimetic peptides and methods of treatment
US9173890B2 (en) * 2007-09-20 2015-11-03 Abbott Cardiovascular Systems Inc. Sustained release of Apo A-I mimetic peptides and methods of treatment
US8101565B2 (en) * 2007-09-20 2012-01-24 Abbott Cardiovascular Systems Inc. Sustained release of Apo A-I mimetic peptides and methods of treatment
US7985728B1 (en) 2007-09-20 2011-07-26 Abbott Cardiovascular Systems Inc. Sustained release of Apo A-I mimetic peptides and methods of treatment
US7985727B1 (en) 2007-09-20 2011-07-26 Abbott Cardiovascular Systems Inc. Apo A-I mimetic peptides and methods of treatment
WO2009129263A1 (en) * 2008-04-15 2009-10-22 The Government Of The Usa As Represented By The Secretary Of The Department Of Health & Human Serv. Peptides promoting lipid efflux via abca1 and activating a lipoprotein lipase
BRPI0915093A2 (pt) * 2008-06-13 2015-10-27 Proyecto Biomedicina Cima Sl conjugados para a administração de compostos biologicamente ativos
PL2355851T3 (pl) 2008-11-10 2018-08-31 Arbutus Biopharma Corporation Nowe lipidy i kompozycje do dostarczania środków terapeutycznych
WO2010088537A2 (en) 2009-01-29 2010-08-05 Alnylam Pharmaceuticals, Inc. Improved lipid formulation
AU2014268255B2 (en) * 2009-02-16 2016-04-21 Cerenis Therapeutics Holding Sa Apolipoprotein a-i mimics
NZ594516A (en) * 2009-02-16 2012-12-21 Cerenis Therapeutics Holding Sa Apolipoprotein a-i mimics
CN104922699B (zh) 2009-03-12 2020-07-24 阿尔尼拉姆医药品有限公司 脂质配制的组合物以及用于抑制Eg5和VEGF基因表达的方法
SG10201402054UA (en) 2009-05-05 2014-09-26 Muthiah Manoharan Lipid compositions
EP3431076B1 (de) 2009-06-10 2021-10-06 Arbutus Biopharma Corporation Verbesserte lipidformulierung
US9029338B2 (en) 2009-08-14 2015-05-12 Alnylam Pharmaceuticals, Inc. Lipid formulated compositions and methods for inhibiting expression of a gene from the ebola virus
WO2011044545A2 (en) 2009-10-09 2011-04-14 Sigalov Alexander B Methods and compositions for targeted imaging
US10894098B2 (en) 2012-04-09 2021-01-19 Signablok, Inc. Methods and compositions for targeted imaging
US9687550B2 (en) 2009-12-07 2017-06-27 Arbutus Biopharma Corporation Compositions for nucleic acid delivery
WO2011075656A1 (en) 2009-12-18 2011-06-23 The University Of British Columbia Methods and compositions for delivery of nucleic acids
US20130156845A1 (en) 2010-04-29 2013-06-20 Alnylam Pharmaceuticals, Inc. Lipid formulated single stranded rna
WO2011143362A1 (en) 2010-05-11 2011-11-17 Esperion Therapeutics, Inc. Dimeric oxidation-resistant apolipoprotein a1 variants
ES2634087T3 (es) 2010-06-03 2017-09-26 Alnylam Pharmaceuticals, Inc. Lípidos biodegradables para la administración de agentes activos
US20130323269A1 (en) 2010-07-30 2013-12-05 Muthiah Manoharan Methods and compositions for delivery of active agents
US20130202652A1 (en) 2010-07-30 2013-08-08 Alnylam Pharmaceuticals, Inc. Methods and compositions for delivery of active agents
WO2012064824A1 (en) 2010-11-09 2012-05-18 Alnylam Pharmaceuticals, Inc. Lipid formulated compositions and methods for inhibiting expression of eg5 and vegf genes
WO2012092365A1 (en) 2010-12-31 2012-07-05 Alphacore Pharma Llc Detection of lcat activity
JP5902197B2 (ja) 2011-01-11 2016-04-13 アルニラム・ファーマシューティカルズ・インコーポレーテッド Ｐｅｇ化脂質および薬剤送達のためのそれらの使用
SMT201900045T1 (it) 2011-02-07 2019-02-28 Cerenis Therapeutics Holding Sa Complessi lipoproteici e loro produzione e usi
WO2012162392A1 (en) 2011-05-23 2012-11-29 Timothy Hla Endothelium protective materials and methods of use
US9701623B2 (en) 2011-09-27 2017-07-11 Alnylam Pharmaceuticals, Inc. Di-aliphatic substituted pegylated lipids
CN104220460A (zh) * 2011-12-08 2014-12-17 安姆根有限公司 激动人lcat抗原结合蛋白和它们在疗法中的用途
WO2014144708A1 (en) 2013-03-15 2014-09-18 The Regents Of The University Of California Peptides having reduced toxicity that stimulate cholesterol efflux
CN104250288B (zh) * 2013-06-28 2018-02-27 清华大学 两亲性α螺旋自组装肽及其应用
EP2853259A1 (de) 2013-09-30 2015-04-01 Université Pierre et Marie Curie (Paris 6) Rekonstituierte hochdichte Lipoproteinzusammensetzung und Verwendungen davon
MX2016014306A (es) 2014-05-02 2017-06-12 Cerenis Therapeutics Holding Sa Marcadores para terapia con lipoproteinas de alta densidad (hdl).
US10220046B2 (en) 2014-07-14 2019-03-05 The Regents Of The University Of Michigan Compositions and methods for disease treatment using nanoparticle delivered compounds
CN107074923B (zh) 2014-07-31 2021-08-03 Uab研究基金会 Apoe模拟肽及对清除血浆胆固醇的较高效力
AU2016238290B9 (en) 2015-03-25 2019-06-13 The Regents Of The University Of Michigan Compositions and methods for delivery of biomacromolecule agents
JP2018528257A (ja) 2015-07-10 2018-09-27 ペプティノボ・バイオファーマ・リミテッド・ライアビリティ・カンパニーＰｅｐｔｉｎｏｖｏ Ｂｉｏｐｈａｒｍａ， ＬＬＣ 疎水性薬剤の効能を改善するための配合物
EP3554531A1 (de) * 2017-01-24 2019-10-23 MacRegen, Inc. Behandlung von altersbedingter degeneration und anderen augenkrankheiten mit apolipoproteinmimetika
ES2984285T3 (es) 2017-08-10 2024-10-29 Abionyx Pharma Sa Cargómeros
CA3083194A1 (en) 2017-11-22 2019-05-31 Hdl Therapeutics, Inc. Systems and methods for priming fluid circuits of a plasma processing system
CN112040932A (zh) 2017-12-28 2020-12-04 Hdl治疗公司 一种保存和给药自人类血浆提取的前-β高密度脂蛋白的方法
IT201900000651A1 (it) 2019-01-16 2019-04-16 Pastore Lucio Tecnologia di trasferimento genico
JP2023522889A (ja) 2020-04-16 2023-06-01 アビオニクス ファーマ エスエー 脂質結合タンパク質ベースの複合体を使用した、急性病態を治療するための方法
MX2022012906A (es) 2020-04-16 2023-03-14 Abionyx Pharma Sa Terapia con cer-001 para tratar enfermedad renal.
MX2023003877A (es) 2020-10-01 2023-04-18 Abionyx Pharma Sa Composiciones que comprenden complejos basados en proteina de union a lipidos para usarse en el tratamiento de enfermedades oculares.
CA3216226A1 (en) 2021-04-15 2022-10-20 Abionyx Pharma Sa Use of lipid binding protein-based complexes in organ preservation solutions
CN115300609A (zh) * 2021-05-08 2022-11-08 西湖大学 缺氧诱导脂滴相关蛋白(hilpda)在预防或治疗高血脂相关疾病中的应用
JP2025512987A (ja) 2022-04-06 2025-04-22 アビオニクス ファーマ エスエー 脂質結合タンパク質に基づく複合体を使用して白血球増加、内皮機能不全、および心臓炎を処置する方法
JP2025511845A (ja) 2022-04-06 2025-04-16 アビオニクス ファーマ エスエー 脂質結合タンパク質ベースの複合体を使用した、眼疾患を治療するための方法
EP4536268A2 (de) 2022-06-10 2025-04-16 Abionyx Pharma SA Verfahren zur behandlung von hyperentzündungskrankheiten mit lipidbindenden komplexen auf proteinbasis
AU2023284357A1 (en) 2022-06-10 2025-01-23 Abionyx Pharma Sa Methods for treating acute conditions using lipid binding protein-based complexes
WO2024150064A1 (en) 2023-01-13 2024-07-18 Abionyx Pharma Sa Lipid binding protein molecule therapy
WO2025093929A1 (en) 2023-10-31 2025-05-08 Abionyx Pharma Sa Lipid binding protein molecule therapy

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH621479A5 (de) * 1977-08-05 1981-02-13 Battelle Memorial Institute
CA1173360A (en) * 1979-06-22 1984-08-28 Jurg Schrank Pharmaceutical preparations
DE3241102A1 (de) * 1982-11-06 1984-05-10 A. Nattermann & Cie GmbH, 5000 Köln Imidazolylalkylthienyl-tetrahydropyridazine und verfahren zu ihrer herstellung
US4643988A (en) 1984-05-15 1987-02-17 Research Corporation Amphipathic peptides
US4880635B1 (en) * 1984-08-08 1996-07-02 Liposome Company Dehydrated liposomes
US4857319A (en) * 1985-01-11 1989-08-15 The Regents Of The University Of California Method for preserving liposomes
CA2137814A1 (en) * 1992-06-12 1993-12-23 Maryvonne Rosseneu New peptides and proteins, process for their preparation and their use as cholesterol acceptors
US5674855A (en) * 1992-08-12 1997-10-07 The Rogosin Institute Methods and compositions useful in prophylaxis and therapy of endotoxin related conditions
SE9203753D0 (sv) * 1992-12-11 1992-12-11 Kabi Pharmacia Ab Expression system for producing apolipoprotein ai-m
FR2723741A1 (fr) * 1994-08-16 1996-02-23 Fournier Sca Lab Peptides inhibiteurs de la proteine de transfert des esters de cholesterol et leur utilisation en therapeutique
FR2734568B1 (fr) * 1995-05-22 1997-06-20 Rhone Poulenc Rorer Sa Nouveaux variants de l'apolipoproteine
AU710061B2 (en) * 1996-03-29 1999-09-09 Dario Boffelli Amphipathic molecules as cholesterol and other lipid uptake inhibitors
GB9609702D0 (en) * 1996-05-09 1996-07-10 Royal Free Hosp School Med Anticoagulant peptides
US6037323A (en) * 1997-09-29 2000-03-14 Jean-Louis Dasseux Apolipoprotein A-I agonists and their use to treat dyslipidemic disorders
US6004925A (en) * 1997-09-29 1999-12-21 J. L. Dasseux Apolipoprotein A-I agonists and their use to treat dyslipidemic disorders
US6046166A (en) * 1997-09-29 2000-04-04 Jean-Louis Dasseux Apolipoprotein A-I agonists and their use to treat dyslipidemic disorders

Also Published As

Publication number Publication date
KR100650953B1 (ko) 2006-11-29
EP1019074A1 (de) 2000-07-19
CA2304988C (en) 2011-01-04
AU2002300464C1 (en) 2003-02-13
RU2214831C2 (ru) 2003-10-27
KR20010030804A (ko) 2001-04-16
UA71552C2 (uk) 2004-12-15
EP1019074B1 (de) 2007-05-23
US20060252694A1 (en) 2006-11-09
NO329204B1 (no) 2010-09-13
WO1999016458A1 (en) 1999-04-08
JP2001517710A (ja) 2001-10-09
PL339745A1 (en) 2001-01-02
CA2304988A1 (en) 1999-04-08
NO20001598D0 (no) 2000-03-28
US20050080013A1 (en) 2005-04-14
US7566695B2 (en) 2009-07-28
HUP0103114A3 (en) 2003-09-29
CN1280500A (zh) 2001-01-17
AU2002300464B2 (en) 2006-05-18
ES2287982T3 (es) 2007-12-16
CN1699410A (zh) 2005-11-23
NZ503718A (en) 2002-08-28
AU746686B2 (en) 2002-05-02
US6046166A (en) 2000-04-04
DE69837809T2 (de) 2008-01-31
US7157425B2 (en) 2007-01-02
PL196676B1 (pl) 2008-01-31
US20050203284A9 (en) 2005-09-15
US20030060604A1 (en) 2003-03-27
ATE362766T1 (de) 2007-06-15
HUP0103114A2 (hu) 2001-11-28
NO20001598L (no) 2000-05-02
CN1198640C (zh) 2005-04-27
US7273848B2 (en) 2007-09-25
US6900177B1 (en) 2005-05-31
IL135319A0 (en) 2001-05-20
EP1019074A4 (de) 2003-07-23
AU1063399A (en) 1999-04-23

Similar Documents

Publication Publication Date Title
DE69837809D1 (de) Apolipoprotein a-i agonisten sowie deren verwendung zur behandlung dislipidemischer erkrankungen
ATE556713T1 (de) Omega-carboxyarylsubstituierte-diphenyl- harnstoffe als p38-kinasehemmer
RS50091B (sr) Upotreba retigabina u lečenju neuropatskog bola
EA200300248A1 (ru) Бициклопиразолы, активные в качестве ингибиторов киназы, способ их получения и включающие их фармацевтические композиции
AR008853A1 (es) Nuevos compuestos farmaceuticamente activos, su uso en la fabricacion de medicamentos, metodo de tratamiento, composicion farmaceutica, compuestosintermediarios y proceso para la fabricacion de dichos compuestos
PT804252E (pt) Agentes queladores metalicos que contem monoaminas diamidas e tiois
BR9908332A (pt) Derivados de n-[carbonil(anel di ou triaza diinsaturado de cinco membros substituìdo)] derivados de guanidina para tratamento de esquemia
DE69729125D1 (de) Troponin untereinheiten und fragmente zur verwendung als inhibitoren der angiogenese
BG104599A (en) Inhibition of raf kinase using symmetrical and unsymmetrical substituted diphenyl ureas
DE69736441D1 (de) Pharmazeutische zusammensetzung zur behandlung von neurologischen und neuropsychiatrischen erkrankungen
BR0116452A (pt) Composto, composição farmacêutica, uso de um composto
AP9901435A0 (en) Bicycle heteroaromatic compounds as protein tyrosine kinase inhibitors.
DK0725779T3 (da) Hidtil ukendte (R)-5-Carbamoyl-8-fluor-3-N,N-disubstitueret-amino-3,4-dihydro-2H-1-benzopyraner
NO976048D0 (no) Farmasöytiske og diett formuleringer for profylakse og behandling av mave- og tarmforstyrrelser
DE60315479D1 (de) Pyrimidinamid derivate und deren verwendung
BR0312722A (pt) Derivados de pirazol heterobicìclico como inibidores de qinase
DK0556332T3 (da) Substituerede tetrahydropyridiner og hydroxypiperidiner som midler til behandling af centralnervesystemet
DK1032556T3 (da) Farmaceutisk aktive forbindelser og anvendelsesfremgangsmåder
AU6469401A (en) Pharmaceutically active compounds and methods of use
ATE287886T1 (de) Verwendung von 5-thio, sulfinyl- und sulfonylpyrazolo 3,4-b) pyridinen als cyclin- abhängige kinase-hemmer
BR0012327A (pt) Pirrolidinas e piperidinas neurotróficas, e composições e métodos relacionados
ES2088128T3 (es) Aminosulfonilureas inhibidoras de acat.
ATE290857T1 (de) Bretyliumhaltige zusammensetzungen und kits und deren verwendung zur vorbeugung und behandlung cardiovaskulärer erkrankungen
BR9811348A (pt) Compostos derivados de indol, processo para preparação dos mesmos, e, composições farmacêuticas.
ATE213233T1 (de) Substituierte caprolactame und deren derivate verwendbar zur behandlung der hiv-krankheit

Legal Events

Date Code Title Description
8364 No opposition during term of opposition